The full product name Quchong Zhili Mixture Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions identifies a multi-active veterinary pharmaceutical starting material manufactured under cGMP controls and supplied for further processing into seven administration routes. For supply-chain identification, the grade is designated in this document as QZM-VET-API; manufacturer-specific lot codes may append the drying or micronization process, such as QZM-VET-API-SD for spray-dried material or QZM-VET-API-JM for nitrogen-purged jet-milled material. The mixture is a fixed-ratio blend of antiparasitic or anthelmintic active compounds, with the qualitative and quantitative composition declared on the batch certificate of analysis. Because the exact active ratio is manufacturer-specific and may vary by target dosage form, the batch dossier rather than a general monograph is the controlling specification. Unlike a single-entity veterinary API, QZM-VET-API shifts the burden of multi-active blend homogeneity, particle size conditioning, and impurity control from the downstream finished-product plant to the API manufacturer.

The term “Veterinary Grade API” is not a pharmacopoeial monograph title; it is a supply-chain grade designation indicating compliance with 21 CFR 210/211 current good manufacturing practice for finished pharmaceuticals, VICH GL18 for impurities in new veterinary drug substances, and the applicable monographs for each active component. The material is released only after batch records confirm that blending time, drying temperature, micronization pressure, and packaging conditions remain within qualified ranges. The manufacturing line typically includes a high-shear granulator for wet processing, a spray dryer for heat-sensitive lots, and a jet mill with nitrogen purge for particle size reduction. Because the mixture contains multiple active compounds, the supplier’s analytical method validation must resolve co-eluting related substances and demonstrate specificity for each active in the presence of oxidative and hydrolytic degradation products.

What Release Criteria Distinguish Veterinary-Grade API From Technical-Grade Blends?

The release dossier for QZM-VET-API follows the impurity-control logic of VICH GL18 and the stability logic of VICH GL11, supplemented by Ph. Eur. and USP general chapters. A veterinary-grade mixture is not defined solely by total activity; it is defined by the completeness of the impurity profile, residual solvent control, microbial burden, and particle size distribution. For each batch, the certificate of analysis typically reports identification of each active by high-performance liquid chromatography with diode-array detection or by the dossier method, assay of each active at 95.0–105.0% of the declared ratio, total related substances not more than 2.0%, and any individual unspecified impurity not more than 0.2%. Residual solvents are controlled against Ph. Eur. 5.4 or USP <467>. Loss on drying is commonly controlled at ≤ 5.0% for spray-dried lots, with residue on ignition ≤ 0.1% for non-mineral-loaded grades. These are release criteria, not end-use performance values; the formulator must still verify blend uniformity, potency recovery, and process-specific stability in the finished product.

Physical characterisation includes laser diffraction, scanning electron microscopy, and powder rheometry. The mixture is controlled for bulk density, tapped density, and compressibility because these parameters determine flow through rotary press feed frames and capsule-filling dosators. For spray-dried lots, primary particle diameter typically lies between 10 µm and 75 µm, with agglomerate size controlled by subsequent milling. The material can be hygroscopic; production-scale loss-on-drying data indicate that moisture uptake rises above 60% RH, and open handling in an uncontrolled humidity area can increase moisture by 0.5–1.0% within 30 minutes. Dispensing is therefore performed in dry areas with relative humidity ≤ 40%, and lot-specific moisture verification is recommended before weighing. The mixture should not be dry-blended with strongly acidic carriers or strong oxidizing agents because such contact can reduce assay recovery and increase related substances; compatibility testing under VICH GL11-aligned stress conditions is required before reformulation. Published data for this specific multi-active mixture under all site-specific conditions are limited, so the manufacturer’s stability programme and certificate of analysis remain the primary sources of retest dating.

If Sterile Solutions Are Prepared, Sterility Assurance Cannot Be Retrospectively Added

Injectable dosage forms require complete dissolution or controlled suspension in water-for-injection or a suitable co-solvent system. The mixture is not inherently sterile, and sterility cannot be ensured by testing alone; the finished product must be sterilized by a validated method. For heat-labile formulations, filtration through 0.22 µm membrane filters is used, but the API lot must carry a bioburden low enough to avoid filter challenge exceeding the validated capacity. Bacterial endotoxin is controlled because sterilizing filtration does not remove endotoxin. The API manufacturer produces injectable-grade lots in ISO 14644 cleanroom zones, transfers material in sealed stainless-steel or HDPE containers, and samples through closed ports. Release for injectable use relies on Ph. Eur. 2.6.14 or USP <85> endotoxin testing and on the finished-product sterility test per USP <71> or Ph. Eur. 2.6.1 after terminal processing.

Dissolution behaviour in aqueous vehicles is pH-dependent, and each active in the mixture must be assessed separately. A forced degradation study covering pH 2.0, pH 6.8, and pH 10.0 is used to identify degradation peaks and to set hold-time limits for the bulk solution. The least soluble active determines the required co-solvent ratio, and the formulator must confirm that the selected co-solvent does not reduce the solubility of a second active. Sub-visible particulate burden is evaluated on the formulated solution using USP <788> or Ph. Eur. 2.9.19, because insoluble impurities or excipient interactions can produce light-obscuration counts that cannot be detected by visual inspection alone. Published data specific to terminal autoclave cycles for this exact mixture remain limited; therefore, if terminal steam sterilisation is selected, the finished-product manufacturer must perform a steam sterility validation and confirm active recovery after the cycle.

Tablet and capsule manufacture uses QZM-VET-API as a pre-blended active phase. Direct compression requires a first pre-mix with a suitable filler such as spray-dried lactose or microcrystalline cellulose at a ratio of not more than 1:20 to avoid active-enriched agglomerates; the pre-mix is then discharged through a 500 µm screen before final blending. On rotary tablet presses, ejection force and die-wall friction are monitored because fine-particle content can increase sticking and capping. Capsule filling on dosator or tamping-pin machines requires plug density in the range 0.45–0.70 g/cm³ to maintain weight stability. Wet granulation is preferred for high-dose tablets because it improves content uniformity and reduces dust. In high-shear granulation, the binder solution is sprayed into a mixer with impeller speed 150–250 rpm and chopper speed 1,500–2,500 rpm; granules are dried in a fluid-bed dryer with inlet air temperature not exceeding 55°C until loss on drying is below 3.0%. These process windows apply to typical multi-active anthelmintic formulations, but they must be confirmed by site-specific thermal and shear compatibility studies.

Feed premixes are produced by blending the API with feed-grade carriers in a ribbon blender. The mixture is typically diluted to 5–20% active premix before further dilution at the feed mill, and blend uniformity is verified at three discharge times against a coefficient of variation not more than 5.0%. Segregation can occur during transfer if the carrier particle size distribution is too broad; therefore, the carrier is conditioned to approximately 250–1,000 µm, and long-distance pneumatic conveying is avoided. Oral solutions are prepared by dissolving or suspending the mixture in purified water or a co-solvent system; pH is adjusted to the target range and viscosity is controlled with sodium carboxymethylcellulose or xanthan gum. Because the product contains multiple actives, each active’s solubility and chemical stability must be validated independently rather than inferred from total dissolved solids.

Elemental Impurities, Residual Solvents, and Microbial Burden

Elemental impurities are controlled using USP <232> and USP <233>, with analysis by inductively coupled plasma–mass spectrometry on dissolved or microwave-digested samples. The analytical target includes lead, cadmium, mercury, and arsenic, as well as chromium, nickel, copper, and molybdenum when justified by the synthetic route. The acceptance limit for injectable-grade lots is derived from the permitted daily exposure described in ICH Q3D. Residual solvents are determined by headspace gas chromatography and reported against Ph. Eur. 5.4 or USP <467>. If a Class 2 solvent appears in the synthetic route, it is controlled to the specific concentration limit; Class 3 solvents are controlled to ≤ 0.5% unless otherwise specified in the dossier.

The microbial quality of non-sterile lots follows Ph. Eur. 5.1.4 or USP <1111>; total aerobic microbial count is generally set at ≤ 1 × 10³ cfu/g, and yeast and mould count at ≤ 1 × 10² cfu/g. Specified pathogens are assessed by absence in 1 g or 10 g samples as required by the target dosage form. For injectable lots, environmental monitoring data and water-for-injection system validation are reviewed during supplier qualification, and bacterial endotoxin testing is performed on every batch because the API is not sterile and downstream filtration does not remove pyrogens.

In commercial practice, the principal difference between QZM-VET-API and a simple co-blended veterinary powder is the degree of pre-release verification and physical conditioning. Single-entity anthelmintics require multiple weighments at the dispensing pharmacy or manufacturing plant; each weighment carries its own assay, impurity, and particle-size distribution risk. The pre-compounded mixture reduces the number of active weighments to one and transfers blend homogeneity responsibility to the API manufacturer. Compared with technical-grade blends, veterinary-grade material provides pharmacopoeial method validation, elemental impurity profiles, endotoxin control for injectable lots, and route-specific particle size. Technical-grade products are generally intended for agricultural or non-pharmaceutical use and do not carry pharmacopoeial impurity or microbial controls.

The choice between this mixture and alternative sources should be based on the full supplier dossier, including method validation reports, stability summaries, residual solvent declarations, and site audit status. No API grade can guarantee finished-product performance; the downstream manufacturer retains responsibility for formulation development, process validation, and product stability under the target veterinary marketing authorization.